J Cardiol 2004 Apr; 434: 185 191 3: Fulminant Myocarditis Treated With Percutaneous Cardiopulmonary Support and Long-Term Complications: Three Case Reports Tetsuro KUSABA, MD Yoshifumi NAKAHARA, MD Akiyoshi MATSUMURO, MD Takashi NAKAMURA, MD Shohei SAWADA, MD Abstract A 16-year-old female underwent percutaneous cardiopulmonary supportpcpsfor treatment-resistant ventricular tachycardia, but she could not be weaned from PCPS early without complications. A 44-yearold female underwent PCPS for low cardiac output syndrome with mainly heparin used for anticoagulation. With long-term PCPS, the activated clotting time became unstable, and she died due to fatal hemorrhagic complications in the acute stage. A 71-year-old female underwent PCPS for low cardiac output syndrome with mainly nafamostat mesilate used for anticoagulation. Despite long-term extracorporeal circulation, she was weaned from PCPS without hemorrhagic complications. However, she died of multiple organ failure and systemic cytomegalovirus infection in the chronic stage. Myocardial recovery was delayed in Cases 2 and 3, so long-term PCPS was required, which resulted in severe complications. To prevent hemorrhagic complications, nafamostat mesilate should be given and activated clotting time should be measured frequently. To prevent multiple organ failure, the appropriate initial PCPS flow should be established after the evaluation of urinary output, saturation of venous oxygen, and splanchnic circulation such as arterial ketone body ratio and gastric acid secretion. J Cardiol 2004 Apr; 434: 185191 Key Words Myocarditis fulminant Heart failure, treatment Complications Extracorporeal circulation percutaneous cardiopulmonary support Anticoagulants 13 percutaneous cardiopulmonary support: PCPS 2002 52 4 2 PCPS 3 PCPS 1 16Table 1Fig. 1 2001 4 11 : 5203046 421 Division of Cardiology, Saiseikai Shiga Hospital, Shiga Address for correspondence : KUSABA T, MD, Division of Cardiology, Saiseikai Shiga Hospital, Ohashi 421, Ritto, Shiga 520 3046 Manuscript received August 25, 2003; revised October 24, 2003 ; accepted November 10, 2003 185
186 PCPS management Table 1Comparison of therapy between patients and national survey 4 Case 1 Case 2 National survey in Japan Non-survivors Period from admission to starting PCPS Same day 2 days 4 days 0.9 day Administration timehr 45 185 285 187.2 Indications LTA LOS LOS LOS : LTA27 : 23 Initial PCPS flowl/min, meansd Exchange of PCPS Anticoagulants Other extracorporeal circulation IABP CHDF 5 Heparin 3 3 times Heparin 2.5 3 times Nafamostat mesilate 2.890.7 3n15 8n24 2.390.8 7n11 15n21 Temporary pacing Plasma exchange Medication Catecholamine Steroid Antibiotics Gamma globulin Complications IPM/CS, MINO IPM/CS, MINO 4 times IPM/CS, MINO 10n16 6n25 2n11 10n17 Hemorrhagic complications Retroperitoneum, lung Local hemorrhage Life threatening arrhythmia Multiple organ failure Sequela Parameters when weaned from PCPS Vf, cardiac arrest IRBBB Lung, kidney Death CAVB, VF, AF Lung, liver, kidney Death 0n29 31n52 13n21 21n52 Cardiac indexl/min/m 2 Left ventricular ejection fraction% 2.2 33 1.8 42 2.6 57 2 Improvement Left ventricular ejection timemsec 192 190 200200 SvO% 2 66 63 55 60 Total bilirubinmg/dl Acidosis 1.1 5.3 18.63.0 Urinary output Good Good Poor Good Case 3 Survivors Exchange of PCPS shows the number of times in our patients, and the number of patients requiring exchange in the national survey. Not included in national survey in Japan 4. Recommended criteria for weaning from PCPS in the national survey in Japan 4. PCPSpercutaneous cardiopulmonary support ; LTAlife threatening arrhythmia ; LOSlow output syndrome ; IABPintraaortic balloon pumping ; CHDFcontinuous hemodiafiltration ; IPM/CSimipenem/cilastatin ; MINOminocycline hydrochloride ; Vf ventricular fibrillation ; CAVBcomplete atrioventricular block ; VFventricular flutter ; AFatrial flutter ; IRBBBincomplete right bundle branch block ; SvO 2 saturation of venous oxygen. 70mmHg 1 PCPS 34.5 C PCPS 45 PCPS 8 39 23 J Cardiol 2004 Apr; 434: 185 191
187 Fig. 1 Clinography of Case 1 Administration of catecholaminedopamine and/or dobutaminewas adjusted appropriately to maintain mean blood pressure above 80 mmhg. CPK creatine phosphokinase ; FS fractional shortening by echocardiography; m-psl methylprednisolone ; -glb gamma globulin. Other abbreviations as in Table 1. Fig. 2 Clinography of Case 2 ACT activated clotting time ; ET left ventricular ejection time. Other abbreviations as in Table 1, Fig. 1. 67% 2 44 Table 1Fig. 2 2001112712 2 80mmHg50/min QRS 30% intraaortic balloon pumping : IABP J Cardiol 2004 Apr; 434: 185 191
188 Fig. 3 Acute phase clinography of Case 3 T-Bil total bilirubin ; PE plasma exchange ; VVI and DDD pacemaker setting mode. Other abbreviations as in Table 1, Figs. 1, 2. PCPS 1 8 PCPS 3 PCPS 200 185PCPS 42% 3 71 Table 1Fig. 3 2002 12 21 3 PCPS PCPS 4 8 IABP 285PCPS PCPS 4 J Cardiol 2004 Apr; 434: 185 191
189 49 PCPS 4 1 PCPS 5 2PCPS PCPS PCPSPCPS 3 1 150200 PCPS 3 4 ph 5 6 6,7 PCPS 3 ph 4 3 PCPS IABP PCPS PCPS PCPSForrester 2.2 l/min/m 2 PCPS PCPS 8 9 J Cardiol 2004 Apr; 434: 185 191
190 10 52 1 11 2 10 2 PCPS 3 12 30% 4,13 3 PCPS 3 PCPS PCPS 116PCPS 244 PCPS PCPS 371 PCPS PCPS 23 PCPS J Cardiol 2004 Apr; 434: 185191 1Kato S, Morimoto S, Hiramitsu S, Nomura M, Ito T, Hishida H : Use of percutaneous cardiopulmonary support of patients with fulminant myocarditis and cardiogenic shock for improving prognosis. Am J Cardiol 1999 ; 83: 623625, A10 2Westaby S, Katsumata T, Pigott D, Jin XY, Saatvedt K, Horton M, Clark RE: Mechanical bridge to recovery in fulminant myocarditis. Ann Thorac Surg 2000; 70 : 278283 3Ueno K, Konishi T, Fukata M, Furukawa H, Usui H, Kato K: Fulminant myocarditis successfully treated with a left ventricular assist device: A case report. J Cardiol 2003; 41: 249254in Jpn with Eng abstr J Cardiol 2004 Apr; 434: 185 191
191 4Aoyama N, Izumi T, Hiramori K, Isobe M, Kawana M, Hiroe M, Hishida H, Kitaura Y, Imaizumi T, Japanese Investigators of Fulminant Myocarditis : National survey of fulminant myocarditis in Japan : Therapeutic guidelines and long-term prognosis of using percutaneous cardiopulmonary support for fulminant myocarditisspecial report from a scientific committee. Circ J 2002; 66 :133144 5Masai T, Taniguchi K, Kuki S, Yokota T, Yoshida K, Yamamoto K, Matsuda H : Usefulness of continuous air tonometry for evaluation of splanchnic perfusion during cardiopulmonary bypass. ASAIO J 2003; 49: 108111 6 : PCPS J Cardiol 1995; 26Suppl: 249abstr 7 : PCPS 1996 ; 3 Suppl: S138abstr 8 : Prog Med 2000; 20 :9395 9Tomioka N, Kishimoto C, Matsumori A, Kawai C : Effects of prednisolone on acute viral myocarditis in mice. J Am Coll Cardiol 1986 ; 7: 868872 10 : 1998 ; 44 : 449 11Kalayci O, Cataltepe S, Cataltepe O : The effect of bolus methylprednisolone in prevention of brain edema in hypoxic ischemic brain injury : An experimental study in 7-dayold rat pups. Brain Res 1992; 569: 112116 12Kodama M, Okura Y, Hirono S, Hanawa H, Ogawa Y, Itoh M, Izumi T, Aizawa Y: A new scoring system to predict the efficacy of steroid therapy for patients with active myocarditis : A retrospective study. Jpn Circ J 1998 ; 62: 715720 13 : in 57 1983; pp 1627 J Cardiol 2004 Apr; 434: 185 191